Literature DB >> 28318368

The wayward methyl group and the cascade to cancer.

Robert M Hoffman1,2.   

Abstract

We propose here a hypothesis of the cause of cancer that brings together fundamental changes in methyl-group metabolism resulting in methionine dependence and global DNA hypomethylation which destabilizes the genome leading to aneuploid karyotypes which evolve and stabilize into autonomous cancer. Experimental support for this hypothesis is that methioine dependence is a general metabolic defect in caner. Methionine dependence is due to excess use of methionene for aberrant transmethylation reactions that apparently divert methyl groups from DNA. The resulting global DNA hypomethylation is also a general phenomena in cancer. Global hypomethylation leads to an unstable genomes and aneuploid karyotypes, another general phenomena in cancer. The excessive and aberrant use of methionine in cancer is strongly observed in [11C]methionine PET imaging, where high uptake of [11C]methionine results in a very strong and selective tumor signal compared with normal tissue background. [11C]methionine is superior to [18C] fluorodeoxyglucose (FDG)-PET for PET imaging, suggesting methionine dependence is more tumor-specific than glucose dependence.

Entities:  

Keywords:  DNA hypomethylation; aneuploidy; cancer; chromosome instability; methionine; methionine dependence; unbalanced transmethylation

Mesh:

Substances:

Year:  2017        PMID: 28318368      PMCID: PMC5444351          DOI: 10.1080/15384101.2017.1304330

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  61 in total

1.  Chromosomal instability and tumors promoted by DNA hypomethylation.

Authors:  Amir Eden; François Gaudet; Alpana Waghmare; Rudolf Jaenisch
Journal:  Science       Date:  2003-04-18       Impact factor: 47.728

Review 2.  The history of cancer epigenetics.

Authors:  Andrew P Feinberg; Benjamin Tycko
Journal:  Nat Rev Cancer       Date:  2004-02       Impact factor: 60.716

3.  The new anticancer era: Tumor metabolism targeting.

Authors:  Adriana Borriello; Fulvio Della Ragione
Journal:  Cell Cycle       Date:  2017-01-05       Impact factor: 4.534

4.  Rapid appearance of hypomethylated DNA in livers of rats fed cancer-promoting, methyl-deficient diets.

Authors:  E Wainfan; M Dizik; M Stender; J K Christman
Journal:  Cancer Res       Date:  1989-08-01       Impact factor: 12.701

5.  Tissue levels of S-adenosylmethionine and S-adenosylhomocysteine in rats fed methyl-deficient, amino acid-defined diets for one to five weeks.

Authors:  N Shivapurkar; L A Poirier
Journal:  Carcinogenesis       Date:  1983-08       Impact factor: 4.944

Review 6.  Value of 11C-methionine PET in imaging brain tumours and metastases.

Authors:  Andor W J M Glaudemans; Roelien H Enting; Mart A A M Heesters; Rudi A J O Dierckx; Ronald W J van Rheenen; Annemiek M E Walenkamp; Riemer H J A Slart
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-12-12       Impact factor: 9.236

7.  Reduced levels of DNA 5-methylcytosine in metastatic variants of the human melanoma cell line MeWo.

Authors:  R G Liteplo; R S Kerbel
Journal:  Cancer Res       Date:  1987-05-01       Impact factor: 12.701

8.  Elevated overall rates of transmethylation in cell lines from diverse human tumors.

Authors:  P H Stern; R M Hoffman
Journal:  In Vitro       Date:  1984-08

9.  Karyotypic evolutions of cancer species in rats during the long latent periods after injection of nitrosourea.

Authors:  Mathew Bloomfield; Amanda McCormack; Daniele Mandrioli; Christian Fiala; C Marcelo Aldaz; Peter Duesberg
Journal:  Mol Cytogenet       Date:  2014-12-16       Impact factor: 2.009

10.  Somatic DNA Hypomethylation in H. pylori-Associated High-Risk Gastritis and Gastric Cancer: Enhanced Somatic Hypomethylation Associates with Advanced Stage Cancer.

Authors:  Andreas Leodolter; Sergio Alonso; Beatriz González; Matthias P Ebert; Michael Vieth; Christoph Röcken; Thomas Wex; Ullrich Peitz; Peter Malfertheiner; Manuel Perucho
Journal:  Clin Transl Gastroenterol       Date:  2015-04-30       Impact factor: 4.488

View more
  8 in total

1.  Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and prevention.

Authors:  Kei Kawaguchi; Qinghong Han; Shukuan Li; Yuying Tan; Kentaro Igarashi; Tasuku Kiyuna; Kentaro Miyake; Masuyo Miyake; Bartosz Chmielowski; Scott D Nelson; Tara A Russell; Sarah M Dry; Yunfeng Li; Arun S Singh; Mark A Eckardt; Michiaki Unno; Fritz C Eilber; Robert M Hoffman
Journal:  Cell Cycle       Date:  2018-03-19       Impact factor: 4.534

Review 2.  Targeting the methionine addiction of cancer.

Authors:  Joni C Sedillo; Vincent L Cryns
Journal:  Am J Cancer Res       Date:  2022-05-15       Impact factor: 5.942

3.  Linkage of methionine addiction, histone lysine hypermethylation, and malignancy.

Authors:  Jun Yamamoto; Sachiko Inubushi; Qinghong Han; Yoshihiko Tashiro; Norihiko Sugisawa; Kazuyuki Hamada; Yusuke Aoki; Kentaro Miyake; Ryusei Matsuyama; Michael Bouvet; Steven G Clarke; Itaru Endo; Robert M Hoffman
Journal:  iScience       Date:  2022-03-25

4.  Recombinant methioninase (rMETase) is an effective therapeutic for BRAF-V600E-negative as well as -positive melanoma in patient-derived orthotopic xenograft (PDOX) mouse models.

Authors:  Kei Kawaguchi; Kentaro Igarashi; Shukuan Li; Qinghong Han; Yuying Tan; Kentaro Miyake; Tasuku Kiyuna; Masuyo Miyake; Takashi Murakami; Bartosz Chmielowski; Scott D Nelson; Tara A Russell; Sarah M Dry; Yunfeng Li; Michiaki Unno; Fritz C Eilber; Robert M Hoffman
Journal:  Oncotarget       Date:  2017-12-12

5.  Characteristics and Stability Assessment of Therapeutic Methionine γ-lyase-Loaded Polyionic Vesicles.

Authors:  Vasily Koval; Elena Morozova; Svetlana Revtovich; Anna Lyfenko; Arpi Chobanian; Viktoria Timofeeva; Anna Solovieva; Natalya Anufrieva; Vitalia Kulikova; Tatyana Demidkina
Journal:  ACS Omega       Date:  2021-12-27

6.  Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma in a patient-derived orthotopic xenograft (PDOX) mouse model.

Authors:  Kei Kawaguchi; Kentaro Igarashi; Shukuan Li; Qinghong Han; Yuying Tan; Tasuku Kiyuna; Kentaro Miyake; Takashi Murakami; Bartosz Chmielowski; Scott D Nelson; Tara A Russell; Sarah M Dry; Yunfeng Li; Michiaki Unno; Fritz C Eilber; Robert M Hoffman
Journal:  Oncotarget       Date:  2017-08-12

Review 7.  Patient-Derived Orthotopic Xenograft (PDOX) Models of Melanoma.

Authors:  Robert M Hoffman
Journal:  Int J Mol Sci       Date:  2017-08-31       Impact factor: 5.923

8.  Intra-tumor L-methionine level highly correlates with tumor size in both pancreatic cancer and melanoma patient-derived orthotopic xenograft (PDOX) nude-mouse models.

Authors:  Kei Kawaguchi; Qinghong Han; Shukuan Li; Yuying Tan; Kentaro Igarashi; Kentaro Miyake; Tasuku Kiyuna; Masuyo Miyake; Bartosz Chemielwski; Scott D Nelson; Tara A Russell; Sarah M Dry; Yunfeng Li; Arun S Singh; Mark A Eckardt; Michiaki Unno; Fritz C Eilber; Robert M Hoffman
Journal:  Oncotarget       Date:  2018-01-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.